Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 9/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4770021 | 0.96 | PTGS2 (0.37) | MAT2APTGS2PTGESPSEN1PSEN2 | |
| SCHEMBL4775049 | 0.96 | PTGS2 (0.37) | MAT2APTGS2PTGESPSEN1PSEN2 | |
| SCHEMBL27662703 | 0.87 | PRKAA2 (0.36) | MAT2APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4772343 | 0.87 | GLA (0.40) | SIGMAR1KMO | |
| SCHEMBL4772575 | 0.86 | PTGS2 (0.37) | MAT2APTGS2PTGESPSEN1PSEN2 | |
| SCHEMBL4777556 | 0.85 | KMO (0.33) | PTGS2PTGESPSEN1PSEN2APH1B | |
| SCHEMBL4776470 | 0.84 | ALDH1A1 (0.37) | KMOPDE4B | |
| SCHEMBL4772332 | 0.84 | RXRA (0.40) | KMOPDE4B | |
| SCHEMBL4778959 | 0.84 | DPP4 (0.34) | PTGS2PTGESSIGMAR1KMOPDE4B | |
| SCHEMBL27682188 | 0.83 | SIGMAR1 (0.36) | MAT2APSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459451-B2 | e.g. 1-Ethyl-4-(5-methyl-3-pyridyl)-6-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid; phosphodiesterase (PDE)-IV inhibitor or tumor necrosis factor (TNF)- alpha antagonist; autoimmune diseases, antidepressant, anxiolytic agent; polychondritis, scleroderma, fibrosis, arthritis, Alzheimer's disease | ASTELLAS PHARMA INC. (JP) | 2008-12-02 | — | — | US | disclosed |
| EP-1763528-B1 | PYRAZOLOPYRIDINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-11-26 | — | — | EP | disclosed |
| CN-1980927-A | Pyrazolopyridine derivatives | ASTELLAS PHARMA INC (JP) | 2007-06-13 | — | — | CN | disclosed |
| EP-1763528-A1 | PYRAZOLOPYRIDINE DERIVATIVES | Astellas Pharma Inc. (JP) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006004188-A1 | PYRAZOLOPYRIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004003-A1 | Pyrazolopyridine derivatives | ASTELLAS PHARMA INC. (JP) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004003-A1 | Pyrazolopyridine derivatives | PDE4A, PDE3B, PDE5A | MAT2A 3361/4885PTGS2 439/4885PTGES 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.